Publications

AbYlink afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections CPP cyclosporin A Debio 0123 Debio 0228 Debio 025 Debio 0432 Debio 0614 (istaroxime) Debio 0719 Debio 0932 NSCLS Debio 1124 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1347 Debio 1452 Debio 1561 Debio 1562 Debio 1562M Debio 4126 Debio 8609 Sanvar Debio 9902 - ZT-1 EPI-hNE4 FibroTrap fuze Heparins Huperzine-A Multilink naratuximab emtansine (Debio 1562) nucleai Oxaliplatin PLGA Triptorelin

September 19, 2020

3-Years follow-up results of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus Debio 1143 (xevinapant) or placebo in…

September 17, 2020

Safety and efficacy of Xevinapant (Debio 1143), an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in…

August 3, 2020

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind,…

September 24, 2019

Debio 1143 Mode of Action: a Broad Chemo-Radio and Immuno-Therapy Sensitizer

September 24, 2019

Squamous Cell Carcinoma Of The Head & Neck (SCCHN) – Infographic

April 3, 2019

Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…

April 30, 2016

Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

September 21, 2015

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF-alpha-mediated in head and neck squamous cell carcinoma.